You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 712 SBT6290, a systemically administered Nectin-4-directed TLR8 ImmunoTAC (TM) therapeutic, is a potent human myeloid cell agonist for the treatment of Nectin-4-expressing tumors

Article Text

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Novel single-agent immunotherapies
712 SBT6290, a systemically administered Nectin-4-directed TLR8 ImmunoTAC (TM) therapeutic, is a potent human myeloid cell agonist for the treatment of Nectin-4-expressing tumors

https://doi.org/10.1136/jitc-2020-SITC2020.0712

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.